KARPAS 384

Established from peripheral blood of a 48 year-old male with widespread subcutaneous nodules. Biopsy showed high grade Non-Hodgkin lymphoma with numerous mitoses.

Human T-cell non-Hodgkin lymphoma

Not specified

Doubling time approximately 60 hours. Cells grow slowly in suspension in large clumps. Maintain cultures between 3-9 x 10⁵ cells/ml; 5% CO₂; 37 °C. Thaw ampoule and perform a cell count, spin out the DMSO and resuspend in an appropriate volume of media to give a cell concentration of 4-5 x 10⁵ cells/ml. Viability may be poor on resuscitation and may decrease further within the first 48 hours, the culture may appear non-viable at this time. Clusters of cells will eventually appear but this could take 1-2 weeks, during this time large media changes are not recommended. It may take 2-3 weeks for vigorous growth to be established. At subculture perform a cell count and maintain cultures between 3-9 x 10⁵ cells/ml, 5% CO₂, 37 °C. For cryopreservation of KARPAS 384, freeze at approximately 2 x 10⁷ cells/ml in 90% FBS + 10% DMSO.

RPMI 1640 + 2 mM Glutamine + 10% Fetal Bovine Serum (FBS)

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). Use of this product by commercial organizations may require a license agreement. Commercial customers will be contacted by cellscreening@merckgroup.com to provide further information after the order request is submitted. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.